Are patients benefiting from participation in the German skin cancer screening programme? A large cohort study based on administrative data.
Journal
The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
accepted:
15
07
2021
pubmed:
22
7
2021
medline:
4
3
2022
entrez:
21
7
2021
Statut:
ppublish
Résumé
The German programme for skin cancer screening was established in 2008 with the aim of reducing skin cancer mortality. However, the effectiveness and risk-benefit ratio of the programme remain unclear. To compare the mortality rates of patients with melanoma who participate in a screening programme to those who do not. A retrospective cohort study, based on pseudonymized health insurance data of 1 431 327 individuals from Saxony, Germany, was conducted for the period 2010-2016. Patients with prevalent and incident melanoma were defined based on diagnosis, medical procedures and prescriptions. Patients who underwent screening and had a first diagnosis of melanoma within 2 years of screening were assigned to the intervention group. Relative survival and Cox regression were used to assess potential differences in mortality. We identified 4552 individuals with prevalent and 2475 individuals with incident melanoma. The percentage of screening participants (n = 1801) who had locoregional (4·2% vs. 13·5%) and/or distant metastases (4·3% vs. 8·0%), or who were treated with systemic anticancer therapies (11·6% vs. 21·8%) was lower vs. nonparticipants (n = 674). Screening participants had significantly better survival rates. The unadjusted Cox model gave a hazard ratio (HR) of 0·37 [95% confidence interval (CI) 0·30-0·46]. After adjusting for named confounders, the effect remained (HR 0·62, 95% CI 0·48-0·80). Patients who participated in the screening programme had lower mortality than those who had not undergone screening. However, these findings may result from a healthy screen bias and/or overdiagnosis associated with screening, and not from the screening itself.
Sections du résumé
BACKGROUND
The German programme for skin cancer screening was established in 2008 with the aim of reducing skin cancer mortality. However, the effectiveness and risk-benefit ratio of the programme remain unclear.
OBJECTIVES
To compare the mortality rates of patients with melanoma who participate in a screening programme to those who do not.
METHODS
A retrospective cohort study, based on pseudonymized health insurance data of 1 431 327 individuals from Saxony, Germany, was conducted for the period 2010-2016. Patients with prevalent and incident melanoma were defined based on diagnosis, medical procedures and prescriptions. Patients who underwent screening and had a first diagnosis of melanoma within 2 years of screening were assigned to the intervention group. Relative survival and Cox regression were used to assess potential differences in mortality.
RESULTS
We identified 4552 individuals with prevalent and 2475 individuals with incident melanoma. The percentage of screening participants (n = 1801) who had locoregional (4·2% vs. 13·5%) and/or distant metastases (4·3% vs. 8·0%), or who were treated with systemic anticancer therapies (11·6% vs. 21·8%) was lower vs. nonparticipants (n = 674). Screening participants had significantly better survival rates. The unadjusted Cox model gave a hazard ratio (HR) of 0·37 [95% confidence interval (CI) 0·30-0·46]. After adjusting for named confounders, the effect remained (HR 0·62, 95% CI 0·48-0·80).
CONCLUSIONS
Patients who participated in the screening programme had lower mortality than those who had not undergone screening. However, these findings may result from a healthy screen bias and/or overdiagnosis associated with screening, and not from the screening itself.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
69-77Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2021 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
Références
Apalla Z, Lallas A, Sotiriou E et al. Epidemiological trends in skin cancer. Dermatol Pract Concept 2017; 7:1-6.
Apalla Z, Nashan D, Weller RB, Castellsagué X. Skin cancer: epidemiology, disease burden, pathophysiology, diagnosis, and therapeutic approaches. Dermatol Ther (Heidelb) 2017; 7(Suppl. 1):5-19.
Matthews NH, Li WQ, Qureshi AA et al. Epidemiology of Melanoma. Brisbane: Codon Publications, 2017.
Riker AI, Zea N, Trinh T. The epidemiology, prevention, and detection of melanoma. Ochsner J 2010; 10:56-65.
Whiteman DC, Green AC, Olsen CM. The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031. J Invest Dermatol 2016; 136:1161-71.
Shaikh WR, Dusza SW, Weinstock MA et al. Melanoma thickness and survival trends in the United States, 1989 to 2009. J Natl Cancer Inst 2016; 108:djv294.
Brodersen J, Schwartz LM, Heneghan C et al. Overdiagnosis: what it is and what it isn't. BMJ Evid Based Med 2018; 23:1-3.
Welch HG, Mazer BL, Adamson AS. The rapid rise in cutaneous melanoma diagnoses. N Engl J Med 2021; 384:72-9.
Leiter U, Garbe C. Epidemiology of melanoma and nonmelanoma skin cancer - the role of sunlight. Adv Exp Med Biol 2008; 624:89-103.
Schoffer O, Schulein S, Arand G et al. Tumour stage distribution and survival of malignant melanoma in Germany 2002-2011. BMC Cancer 2016; 16:936.
Bundesministerium für Gesundheit. Bekanntmachungen: Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Krebsfrüherkennungs-Richtlinien: Hautkrebs-Screening vom 15. November 2007. 2008 March 28, 2008. Contract No.: 13. Available at: https://www.g-ba.de/downloads/40-268-482/2007-11-15-KFU-Hautkrebsscreening_TrG.pdf (last accessed 6 September 2021).
Stang A, Garbe C, Autier P, Jöckel KH. The many unanswered questions related to the German skin cancer screening programme. Eur J Cancer 2016; 64:83-8.
Trautmann F, Schuler M, Schmitt J. Burden of soft-tissue and bone sarcoma in routine care: estimation of incidence, prevalence and survival for health services research. Cancer Epidemiol 2015; 39:440-6.
Shrank WH, Patrick AR, Brookhart MA. Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med 2011; 26:546-50.
Swart E, Gothe H, Geyer S et al. Good practice of secondary data analysis (GPS): guidelines and recommendations. Gesundheitswesen 2015; 77:120-6.
Eurostat. Revision of the European standard population: report of the Eurostat’s task force. Available at: https://ec.europa.eu/eurostat/web/products-manuals-and-guidelines/-/KS-RA-13-028 (last accessed 17 August 2021).
Perme M, Pavlič K. Nonparametric relative survival analysis with the R package relsurv. J Stat Softw 2018; 87.
Statistisches Bundesamt (Destatis). Periodensterbetafel. Available at: https://www-genesis.destatis.de/genesis/online?sequenz=tabelleErgebnis&selectionname=12621-0001&sachmerkmal=GES&sachschluessel=GESM (last accessed 17 August 2021).
Cox DR. Regression models and life-tables. J R Statist Soc B 1972; 34:187-220.
Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998; 36:8-27.
Garland A, Fransoo R, Olafson K et al. The Epidemiology and Outcomes of Critical Illness in Manitoba. Winnipeg, MB: Manitoba Centre for Health Policy, 2012.
R Core Team. R: a language and environment for statistical computing. Available at: https://www.R-project.org/ (last accessed 17 August 2021).
Therneau T, Grambsch P. Modeling Survival Data: Extending the Cox Model. New York: Springer, 2000.
Duffy SW, Nagtegaal ID, Wallis M et al. Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival. Am J Epidemiol 2008; 168:98-104.
World Medical Association. World Medical Association Declaration of Helsinki. JAMA 2013; 310:2191-4.
Swart E, Schmitt J. [STandardized Reporting Of Secondary data Analyses (STROSA) - a recommendation]. Z Evid Fortbild Qual Gesundhwes 2014; 108:511-16.
von Elm E, Altman DG, Egger M et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007; 147:573-7.
Weiss NS, Rossing MA. Healthy screenee bias in epidemiologic studies of cancer incidence. Epidemiology 1996; 7:319-22.
Morrison AS. Screening in Chronic Disease. Oxford: Oxford University Press, 1985.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70:7-30.
Welch HG, Kramer BS, Black WC. Epidemiologic signatures in cancer. N Engl J Med 2019; 381:1378-86.
Kaiser M, Schiller J, Schreckenberger C. The effectiveness of a population-based skin cancer screening program: evidence from Germany. Eur J Health 2018; 19:355-67.
Katalinic A, Eisemann N, Waldmann A. Skin cancer screening in Germany. Documenting melanoma incidence and mortality from 2008 to 2013. Dtsch Arztebl Int 2015; 112:629-34.
Rembold CM. Number needed to screen: development of a statistic for disease screening. BMJ 1998; 317:307.
Hellmund P, Schmitt J, Roessler M et al. Targeted and checkpoint inhibitor therapy of metastatic malignant melanoma in Germany, 2000-2016. Cancers (Basel) 2020; 12:2354.
Hübner J, Hübner F, Terheyden P, Katalinic A. Trendwende bei der Hautkrebsmortalität. Der Hautarzt 2019; 70:989-92.
Daud A, Gill J, Kamra S et al. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. J Hematol Oncol 2017; 10:3.
Robert Koch Institut. Krebs in Deutschland für 2015/2016. Available at: https://edoc.rki.de/handle/176904/6012 (last accessed 17 August 2021).
Garbe C, Keim U, Eigentler TK et al. Time trends in incidence and mortality of cutaneous melanoma in Germany. J Eur Acad Dermatol Venereol 2019; 33:1272-80.
Sacchetto L, Zanetti R, Comber H et al. Trends in incidence of thick, thin and in situ melanoma in Europe. Eur J Cancer 2018; 92:108-18.